Literature DB >> 3364446

Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population.

T R Gravelyn1, N Brophy, C Siegert, M Peters-Golden.   

Abstract

Although hypophosphatemia has been implicated as a cause of respiratory failure, its impact on respiratory muscle function in patients hospitalized for other reasons remains to be determined. Maximal inspiratory pressures (MIP) and maximal expiratory pressures (MEP) were measured at the bedside in 23 hospitalized patients with serum phosphate levels less than 2.5 mg/dl, and these measurements were repeated daily during phosphate repletion until serum phosphate levels reached the normal range. A control group consisted of 11 normophosphatemic inpatients. Sixteen of 23 hypophosphatemic patients, but none of the control patients (p less than 0.001), exhibited respiratory muscle weakness, defined as a MIP less than 40 cm H2O or a MEP less than 70 cm H2O. The mean initial MIP and MEP values were also significantly lower for the hypophosphatemic group. A significant correlation existed between initial phosphate level and initial MIP value (r = 0.50, p less than 0.02). With phosphate repletion, mean +/- SD MIP increased from -37 +/- 26 cm H2O to -49 +/- 24 cm H2O (p less than 0.003) and MEP from 60 +/- 20 cm H2O to 69 +/- 19 cm H2O (p less than 0.02). It is concluded that respiratory muscle weakness is common among hypophosphatemic patients and improves with phosphate repletion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3364446     DOI: 10.1016/0002-9343(88)90065-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Hypophosphatemia in Critically Ill Children: Risk Factors, Outcome and Mechanism.

Authors:  Satish Kumar Shah; Mohammad Irshad; Nandita Gupta; Sushil Kumar Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2016-07-09       Impact factor: 1.967

2.  Intensity of Renal Replacement Therapy and Duration of Mechanical Ventilation: Secondary Analysis of the Acute Renal Failure Trial Network Study.

Authors:  Shilpa Sharma; Yvelynne P Kelly; Paul M Palevsky; Sushrut S Waikar
Journal:  Chest       Date:  2020-05-26       Impact factor: 9.410

3.  Association of Phosphate-Containing versus Phosphate-Free Solutions on Ventilator Days in Patients Requiring Continuous Kidney Replacement Therapy.

Authors:  Melissa L Thompson Bastin; Arnold J Stromberg; Sethabhisha N Nerusu; Lucas J Liu; Kirby P Mayer; Kathleen D Liu; Sean M Bagshaw; Ron Wald; Peter E Morris; Javier A Neyra
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-27       Impact factor: 10.614

Review 4.  Treatment of hypophosphatemia in the intensive care unit: a review.

Authors:  Daniël A Geerse; Alexander J Bindels; Michael A Kuiper; Arnout N Roos; Peter E Spronk; Marcus J Schultz
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

5.  A novel phosphorus repletion strategy in a patient with duodenal perforation.

Authors:  Thomas Kemmerly; Carolyn Vuong; Jonathan D Kaunitz
Journal:  Nutr Clin Pract       Date:  2014-04-17       Impact factor: 3.080

Review 6.  Renal control of calcium, phosphate, and magnesium homeostasis.

Authors:  Judith Blaine; Michel Chonchol; Moshe Levi
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-06       Impact factor: 8.237

7.  Effect of hypophosphatemia on muscle metabolism after exercise in pigs.

Authors:  L Håglin; B Essén-Gustavsson
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

8.  Severe electrolyte disorders following cardiac surgery: a prospective controlled observational study.

Authors:  Kees H Polderman; Armand R J Girbes
Journal:  Crit Care       Date:  2004-10-22       Impact factor: 9.097

9.  Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy.

Authors:  Gabriela Godaly; Ola Carlsson; Marcus Broman
Journal:  Clin Kidney J       Date:  2015-12-19

10.  Hypophosphatemia promotes lower rates of muscle ATP synthesis.

Authors:  Dominik H Pesta; Dimitrios N Tsirigotis; Douglas E Befroy; Daniel Caballero; Michael J Jurczak; Yasmeen Rahimi; Gary W Cline; Sylvie Dufour; Andreas L Birkenfeld; Douglas L Rothman; Thomas O Carpenter; Karl Insogna; Kitt Falk Petersen; Clemens Bergwitz; Gerald I Shulman
Journal:  FASEB J       Date:  2016-06-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.